Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
03/2003
03/13/2003US20030050275 Partial and full agonists of A1 adenosine receptors
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050269 Polynucleotides and polypeptides of the erythropoietin gene
03/13/2003US20030050265 A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding transforming growth factor-beta 2
03/13/2003US20030050250 Administering an aromatic dipeptide derivative with a chemotherapeutic agent to treat tumor metastasis, solid tumor growth, angiogenesis and other neoplasia diseases
03/13/2003US20030050249 Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction
03/13/2003US20030050247 Peptides which are modified with at least one hydrocarbyl group and which possess antimicrobial acitivity
03/13/2003US20030050246 Peptides having antiangiogenic activity
03/13/2003US20030050245 A protein molecule that is a cofactor of tissue plasminogen activator and has a residue of lysine and/or arginine or an equivalent; angiogenesis inhibitors; antiinflammatory agents; antitumor agents; aging; degrads amyloid
03/13/2003US20030050235 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
03/13/2003US20030050234 Conotoxin peptide extracted from the venom of a marine snail, Conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics
03/13/2003US20030050230 A nucleic acid encoding a family (title) of kinases from a group of sixteen polypeptides; identifying a substance that modulates kinase activity; autoimmune diseases; organ transplantation, cardiovascular disease, stroke, renal failure
03/13/2003US20030050228 Administering by mouth an effective amount of an insulin polypeptide derivative within one hour of ingestion of a meal by the patient to provide an insulin drug concentration in portal vein blood of 10-1,000 U/ml within 60 minutes
03/13/2003US20030049843 Gene delivery vectors with cell type specificity for mesenchymal stem cells
03/13/2003US20030049823 eNOS mutations useful for gene therapy and therapeutic screening
03/13/2003US20030049732 Apoptosis related polynucleotides, polypeptides, and antibodies
03/13/2003US20030049706 Nucleotide sequences coding polypeptide for use in the diagnosis, treatment and prevention of bacterial infections
03/13/2003US20030049697 Detection of potassium channel modulators for treatment of heart, vascular and endrocrine pathologies; obtain sample, incubate with modulator, monitor effect of modulator on transport protein activity
03/13/2003US20030049662 Oligonucleotides for use in the treatment of wounds, cardiovascular, cell proliferative and developmental disorders
03/13/2003US20030049643 G protein-coupled receptors for use in the treatment of cardiovascular, nervous system, angina pectoris, inflamatory bowel, allergies and gastrointestinal disorders
03/13/2003US20030049337 Using eucalyptus plant extract
03/13/2003US20030049260 Method of improving cognitive function
03/13/2003US20030049258 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle
03/13/2003US20030049255 Interleukin-1 receptors in the treatment of diseases
03/13/2003US20030049245 Methods for sterilizing preparations of digestive enzymes
03/13/2003US20030049208 For delivering a medicant; product includes a coating having a medicament or agent; bioavailabilty; chewing gum product that releases caffiene for improved performance
03/13/2003CA2459937A1 Ncam binding compounds
03/13/2003CA2459584A1 Compositions and use thereof in the treatment of cancer
03/13/2003CA2459413A1 Methods for sterilizing preparations containing albumin
03/13/2003CA2459346A1 Benzothiazepine derivatives
03/13/2003CA2459161A1 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003CA2459136A1 A caspase-8 binding protein, its preparation and use
03/13/2003CA2459045A1 Antidiabetic extracts of artemisia dracunculus
03/13/2003CA2459017A1 Medicinal compositions containing angiotensin ii receptor antagonist
03/13/2003CA2458883A1 Methods of treating mycocardial event related conditions with thymosin beta 4
03/13/2003CA2458798A1 Method for reducing hypertension and heart failure
03/13/2003CA2458682A1 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003CA2458555A1 Use of c2-substituted indane-1-one systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003CA2458553A1 Use of polysubstituted indan-1-ol systems for producing drugs used in the prophylaxis or treatment of obesity
03/13/2003CA2458526A1 Use of c2-substituted indane-1-ol systems for producing medicaments for the prophylaxis or treatment of obesity
03/13/2003CA2458521A1 Derivatives of c2-substituted indan-1-ol systems, methods for the production thereof and their use as medicaments
03/13/2003CA2458237A1 Vaccine therapies and prophylactic treatments of atherosclerotic diseases
03/13/2003CA2458213A1 Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity
03/13/2003CA2457534A1 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
03/13/2003CA2452438A1 4-thioxo-4,7-dihydro-thieno¬2,3-b|pyridine-5-carbothioamides as antiviral agents
03/13/2003CA2452431A1 4-thioxo-4,7-dihydro-thieno¬2,3-b|pyridine-5-carboxamides as antiviral agents
03/13/2003CA2452044A1 Pre-mixes of glp-1 and basal insulin
03/12/2003WO2002024654A1 Amino heterocyclic compounds (factor xa inhibitors 14)
03/12/2003EP1291360A1 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
03/12/2003EP1291358A1 Feline hepatocyte growth factor
03/12/2003EP1291346A1 Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
03/12/2003EP1291345A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
03/12/2003EP1291343A1 Hydroxyformamidine derivatives and medicines containing the same
03/12/2003EP1291022A1 Methods of using lanreotide, a somatostatin analogue
03/12/2003EP1291019A1 Biologically active agents and drugs
03/12/2003EP1290227A1 Compositions, kits, and methods for identification and modulation of type i diabetes
03/12/2003EP1290193A2 Protein phosphatases
03/12/2003EP1290188A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/12/2003EP1290187A2 Humain kinases
03/12/2003EP1290180A2 Drug metabolizing enzymes
03/12/2003EP1290175A1 Scramblase 2
03/12/2003EP1290174A2 G-protein coupled receptor org3.
03/12/2003EP1290170A2 Binding agents: chimeric ligand/receptor proteins
03/12/2003EP1290169A2 Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
03/12/2003EP1290153A2 Molecular delivery vehicle for delivery of selected compounds to targets
03/12/2003EP1290152A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
03/12/2003EP1290143A2 Method to determine the differentiation potential of a target cell
03/12/2003EP1290033A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
03/12/2003EP1290026A2 Human sez6 nucleic acids and polypeptides
03/12/2003EP1290023A2 Nuclear factor kb inducing factor
03/12/2003EP1290010A1 Pyridine-2-yl-aminoalkyl carbonyl glycyl-$g(b)-alanine and derivatives thereof
03/12/2003EP1290005A2 Vegf-modulated genes and methods employing them
03/12/2003EP1289993A1 Caspase inhibitors and uses thereof
03/12/2003EP1289992A1 New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound
03/12/2003EP1289990A1 Tetracyclic diketopierazine compounds as pdev inhibitors
03/12/2003EP1289989A2 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
03/12/2003EP1289988A1 1,4-diazabicyclo 3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
03/12/2003EP1289987A1 4-(2-phenylthiazol-5-yl)-1,4-diazabicyclo- 3.2.2]nonane derivatives, preparation and therapeutic use thereof
03/12/2003EP1289985A2 Beta-carboline derivatives useful as inhibitors of phosphodiesterase
03/12/2003EP1289983A2 Heteroarylalkanoic acids as integrin receptor antagonists
03/12/2003EP1289982A1 Bioisosteric benzamide derivatives and their use as apob-100 secretion inhibitors
03/12/2003EP1289980A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
03/12/2003EP1289972A1 Serine protease inhibitors
03/12/2003EP1289971A1 Benzamide derivatives and their use as apob-100 and mtp inhibitors
03/12/2003EP1289965A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
03/12/2003EP1289962A1 Integrin ligands
03/12/2003EP1289961A1 Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
03/12/2003EP1289960A2 Cycloalkyl alkanoic acids as integrin receptor antagonists
03/12/2003EP1289959A1 Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
03/12/2003EP1289958A2 BENZOPHENONES AS INHIBITORS OF IL-1$g(b) AND TNF-$g(a)
03/12/2003EP1289957A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
03/12/2003EP1289956A1 Chemical compounds
03/12/2003EP1289955A1 Piperidines for use as orexin receptor antagonists
03/12/2003EP1289950A1 Serine protease inhibitors
03/12/2003EP1289944A2 Thioketals and thioethers for inhibiting the expression of vcam-1
03/12/2003EP1289941A1 Carbamic acid esters as inhibitors of factor xa
03/12/2003EP1289939A1 Phenylglycine derivatives
03/12/2003EP1289916A2 Purification of xanthophylls from marigold extracts that contain high levels of chlorophylls
03/12/2003EP1289576A1 Drug combinations useful for prevention of restenosis
03/12/2003EP1289568A2 Combination product for carrying out a cytotoxic treatment in a mammal
1 ... 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 ... 1595